<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Ann. Oncol</journal-id><journal-id journal-id-type="publisher-id">annonc</journal-id><journal-id journal-id-type="hwp">annonc</journal-id><journal-title-group><journal-title>Annals of Oncology</journal-title></journal-title-group><issn pub-type="ppub">0923-7534</issn><issn pub-type="epub">1569-8041</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27358379</article-id><article-id pub-id-type="pmc">4999563</article-id><article-id pub-id-type="doi">10.1093/annonc/mdw261</article-id><article-id pub-id-type="publisher-id">mdw261</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Gastrointestinal Tumors</subject></subj-group></subj-group><series-title>Editor's choice</series-title></article-categories><title-group><article-title>Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Modest</surname><given-names>D. P.</given-names></name><xref ref-type="aff" rid="mdw261_af1">1</xref><xref ref-type="aff" rid="mdw261_af2">2</xref><xref ref-type="corresp" rid="mdw261_cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Ricard</surname><given-names>I.</given-names></name><xref ref-type="aff" rid="mdw261_af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Heinemann</surname><given-names>V.</given-names></name><xref ref-type="aff" rid="mdw261_af1">1</xref><xref ref-type="aff" rid="mdw261_af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hegewisch-Becker</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="mdw261_af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Schmiegel</surname><given-names>W.</given-names></name><xref ref-type="aff" rid="mdw261_af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Porschen</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="mdw261_af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Stintzing</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="mdw261_af1">1</xref><xref ref-type="aff" rid="mdw261_af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Graeven</surname><given-names>U.</given-names></name><xref ref-type="aff" rid="mdw261_af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Arnold</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="mdw261_af8">8</xref></contrib><contrib contrib-type="author"><name><surname>von Weikersthal</surname><given-names>L. F.</given-names></name><xref ref-type="aff" rid="mdw261_af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Giessen-Jung</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="mdw261_af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stahler</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="mdw261_af1">1</xref><xref ref-type="aff" rid="mdw261_af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Schmoll</surname><given-names>H. J.</given-names></name><xref ref-type="aff" rid="mdw261_af11">11</xref></contrib><contrib contrib-type="author"><name><surname>Jung</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="mdw261_af2">2</xref><xref ref-type="aff" rid="mdw261_af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Kirchner</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="mdw261_af2">2</xref><xref ref-type="aff" rid="mdw261_af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Tannapfel</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="mdw261_af12">12</xref></contrib><contrib contrib-type="author"><name><surname>Reinacher-Schick</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="mdw261_af13">13</xref></contrib><aff id="mdw261_af1"><label>1</label><addr-line>Department of Medical Oncology and Comprehensive Cancer Center</addr-line>, <institution>University Hospital Grosshadern</institution>, <addr-line>Ludwig-Maximilians-Universit&#x000e4;t, Munich</addr-line></aff><aff id="mdw261_af2"><label>2</label><institution>German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ)</institution>, <addr-line>Heidelberg</addr-line></aff><aff id="mdw261_af3"><label>3</label><institution>Institute of Medical Informatics, Biometry and Epidemiology, University of Munich</institution>, <addr-line>Munich</addr-line></aff><aff id="mdw261_af4"><label>4</label><institution>HOPE-Practice for Oncology</institution>, <addr-line>Hamburg</addr-line></aff><aff id="mdw261_af5"><label>5</label><addr-line>Medizinische Klinik</addr-line>, <institution>Knappschaftskrankenhaus Ruhr-Universit&#x000e4;t Bochum</institution>, <addr-line>Bochum</addr-line></aff><aff id="mdw261_af6"><label>6</label><addr-line>Klinik f&#x000fc;r Innere Medizin</addr-line>, <institution>Klinikum Bremen-Ost</institution>, <addr-line>Bremen</addr-line></aff><aff id="mdw261_af7"><label>7</label><addr-line>Kliniken Maria Hilf GmbH, Department of Hematology, Oncology and Gastroenterology, M&#x000f6;nchengladbach</addr-line>, <country>Germany</country></aff><aff id="mdw261_af8"><label>8</label><institution>Instituto CUF de Oncologia</institution>, <addr-line>Lisboa</addr-line>, <country>Portugal</country></aff><aff id="mdw261_af9"><label>9</label><institution>Gesundheitszentrum St Marien</institution>, <addr-line>Amberg</addr-line></aff><aff id="mdw261_af10"><label>10</label><institution>Institute of Pathology University of Munich</institution>, <addr-line>Munich</addr-line></aff><aff id="mdw261_af11"><label>11</label><addr-line>Department of Hematology/Oncology</addr-line>, <institution>University Hospital Halle</institution>, <addr-line>Halle (Saale)</addr-line></aff><aff id="mdw261_af12"><label>12</label><institution>Institute for Pathology, Ruhr-University Bochum</institution>, <addr-line>Bochum</addr-line></aff><aff id="mdw261_af13"><label>13</label><addr-line>Department of Hematology, Oncology and Palliative Care</addr-line>, <institution>St Josef-Hospital, Ruhr University Bochum</institution>, <addr-line>Bochum</addr-line>, <country>Germany</country></aff></contrib-group><author-notes><corresp id="mdw261_cor1"><label>*</label><italic>Correspondence to:</italic> Dr med. Dominik Paul Modest, Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Grosshadern, Marchioninistrasse 15, D-81377 Munich, Germany. Tel: +49-89-4400-72208; Fax: +49-89-4400-75256; E-mail: <email>dominik.modest@med.uni-muenchen.de</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>29</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>6</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>27</volume><issue>9</issue><fpage>1746</fpage><lpage>1753</lpage><history><date date-type="received"><day>9</day><month>5</month><year>2016</year></date><date date-type="rev-recd"><day>20</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>20</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology.</copyright-statement><copyright-year>2016</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri content-type="pdf" xlink:href="mdw261.pdf"/><abstract abstract-type="precis"><p>In this pooled analysis of metastatic colorectal cancer patients, mutations in KRAS, and BRAF were associated with inferior progression-free and overall survival compared with patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D being associated with rather poor survival.</p></abstract><abstract><sec><title>Background</title><p>To explore the impact of <italic>KRAS</italic>, <italic>NRAS</italic> and <italic>BRAF</italic> mutations as well as <italic>KRAS</italic> mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy.</p></sec><sec><title>Patients and methods</title><p>A total of 1239 patients from five randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included into the analysis. Outcome was evaluated by the Kaplan&#x02013;Meier method, log-rank tests and Cox models.</p></sec><sec><title>Results</title><p>In 664 tumors, no mutation was detected, 462 tumors were diagnosed with KRAS-, 39 patients with NRAS- and 74 patients with BRAF-mutation. Mutations in KRAS were associated with inferior progression-free survival (PFS) and overall survival (OS) [multivariate hazard ratio (HR) for PFS: 1.20 (1.02&#x02013;1.42), <italic>P</italic> = 0.03; multivariate HR for OS: 1.41 (1.17&#x02013;1.70), <italic>P</italic> &#x0003c; 0.001]. BRAF mutation was also associated with inferior PFS [multivariate HR: 2.19 (1.59&#x02013;3.02), <italic>P</italic> &#x0003c; 0.001] and OS [multivariate HR: 2.99 (2.10&#x02013;4.25), <italic>P</italic> &#x0003c; 0.001]. Among specific KRAS mutation variants, the KRAS G12C-variant (<italic>n</italic> = 28) correlated with inferior OS compared with unmutated tumors [multivariate HR 2.26 (1.25&#x02013;4.1), <italic>P</italic> = 0.001]. A similar trend for OS was seen in the KRAS G13D-variant [<italic>n</italic> = 71, multivariate HR 1.46 (0.96&#x02013;2.22), <italic>P</italic> = 0.10]. More frequent KRAS exon 2 variants like G12D [<italic>n</italic> = 152, multivariate HR 1.17 (0.86&#x02013;1.6), <italic>P</italic> = 0.81] and G12V [<italic>n</italic> = 92, multivariate HR 1.27 (0.87&#x02013;1.86), <italic>P</italic> = 0.57] did not have significant impact on OS.</p></sec><sec><title>Conclusion</title><p>Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.</p></sec></abstract><kwd-group><kwd>BRAF</kwd><kwd>colorectal cancer</kwd><kwd>mutation</kwd><kwd>prognostic factor</kwd><kwd>RAS</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="mdw261_s1"><title>introduction</title><p><italic>KRAS</italic> exon 2&#x02013;4 and <italic>NRAS</italic> exon 2&#x02013;4 mutations (=<italic>RAS</italic> mutations) are found in &#x0223c;50% of metastatic colorectal cancer (mCRC) tumors and exclude affected patients from epidermal growth factor receptor (EGFR)-directed therapy [<xref rid="MDW261C1" ref-type="bibr">1</xref>&#x02013;<xref rid="MDW261C3" ref-type="bibr">3</xref>]. Besides their negative predictive value, <italic>RAS</italic> mutations may also carry distinct prognostic information [<xref rid="MDW261C4" ref-type="bibr">4</xref>&#x02013;<xref rid="MDW261C6" ref-type="bibr">6</xref>]. Some studies suggest that EGFR inhibition may even be detrimental in patients with <italic>RAS</italic>-mutant mCRC [<xref rid="MDW261C1" ref-type="bibr">1</xref>, <xref rid="MDW261C7" ref-type="bibr">7</xref>] maybe due to interaction with the chemotherapeutic backbone [<xref rid="MDW261C8" ref-type="bibr">8</xref>&#x02013;<xref rid="MDW261C10" ref-type="bibr">10</xref>]. Furthermore, low prevalence of the different <italic>RAS</italic> mutation variants limits conclusions concerning the impact of different subtypes of <italic>RAS</italic> mutation on prognosis so far.</p><p><italic>BRAF</italic> V600E mutation occurs in &#x0223c;5%&#x02013;10% of mCRC tumors [<xref rid="MDW261C1" ref-type="bibr">1</xref>, <xref rid="MDW261C5" ref-type="bibr">5</xref>, <xref rid="MDW261C11" ref-type="bibr">11</xref>]. Despite the limitation of sample size in single trials, <italic>BRAF</italic> mutation represents a consistently poor prognostic marker in the context of mCRC treatment [<xref rid="MDW261C1" ref-type="bibr">1</xref>, <xref rid="MDW261C11" ref-type="bibr">11</xref>, <xref rid="MDW261C12" ref-type="bibr">12</xref>], associated with rapid clinical deterioration after progression to initial therapy [<xref rid="MDW261C12" ref-type="bibr">12</xref>]. However, promising data with combination regimens as well as experimental treatment options may lead to routine assessment of this mutation in mCRC in the near future [<xref rid="MDW261C5" ref-type="bibr">5</xref>, <xref rid="MDW261C13" ref-type="bibr">13</xref>].</p><p>This analysis was designed to explore the prognostic impact of mutations in RAS genes, their subtypes and <italic>BRAF</italic> on outcome of mCRC patients treated within randomized trials of the AIO colorectal cancer study group. With respect to potentially confounding factors of EGFR-based treatment, patients receiving EGFR-targeted agents as first-line therapy were not included.</p></sec><sec sec-type="methods" id="mdw261_s2"><title>patients and methods</title><sec id="mdw261_s2a"><title>studies</title><p>This analysis is based on individual patient data from five first-line trials in mCRC: FIRE-1 [<xref rid="MDW261C14" ref-type="bibr">14</xref>, <xref rid="MDW261C15" ref-type="bibr">15</xref>], FIRE-3 (only bevacizumab-arm) [<xref rid="MDW261C2" ref-type="bibr">2</xref>, <xref rid="MDW261C16" ref-type="bibr">16</xref>, <xref rid="MDW261C17" ref-type="bibr">17</xref>], AIO KRK 0604 [<xref rid="MDW261C18" ref-type="bibr">18</xref>], AIO KRK 0207 [<xref rid="MDW261C19" ref-type="bibr">19</xref>] and RO91 [<xref rid="MDW261C20" ref-type="bibr">20</xref>]. Protocols, responsibilities, declarations of Helsinki, ethical approvals, definitions, treatment schedules and results of the studies were reported previously [<xref rid="MDW261C2" ref-type="bibr">2</xref>, <xref rid="MDW261C14" ref-type="bibr">14</xref>, <xref rid="MDW261C18" ref-type="bibr">18</xref>&#x02013;<xref rid="MDW261C20" ref-type="bibr">20</xref>].</p></sec><sec id="mdw261_s2b"><title>molecular assessment</title><p>Patients were derived from molecularly characterized subsets of the original study-populations (that were evaluated for <italic>KRAS</italic> exon 2 mutations and <italic>BRAF</italic> V600E mutation). FIRE-1, FIRE-3 and AIO KRK 0207 were additionally analyzed for mutations in <italic>KRAS</italic> exon 3&#x02013;4 as well as <italic>NRAS</italic> exon 2&#x02013;4. Methods of testing have been reported in previous publications [<xref rid="MDW261C15" ref-type="bibr">15</xref>&#x02013;<xref rid="MDW261C19" ref-type="bibr">19</xref>, <xref rid="MDW261C21" ref-type="bibr">21</xref>]. Patients were only included into the analysis if a single specified (i.e. including base-exchange) <italic>RAS/BRAF</italic> mutation or no <italic>RAS/BRAF</italic> mutation was present.</p></sec><sec id="mdw261_s2c"><title>patient data</title><p>The following information was assessed for all patients: sex, age, mutation information, treatment, ECOG, location of primary tumor (colon versus rectum), metastatic spread, prior adjuvant chemotherapy, progression-free survival (PFS), overall survival (OS) and response information.</p></sec><sec id="mdw261_s2d"><title>PFS and OS</title><p>PFS was defined as interval between randomization or registration and progression or death from any cause. OS was defined as interval between randomization or registration and death from any cause. For AIO KRK 0207, PFS and OS were calculated from the initial registration (start of induction therapy, and not from randomization for maintenance treatment arms) in order to enable comparison of efficacy parameters [<xref rid="MDW261C19" ref-type="bibr">19</xref>].</p></sec><sec id="mdw261_s2e"><title>influence of treatment on outcome</title><p>The outcome of molecular subgroups was also analyzed in the context of different treatment regimens (oxaliplatin- versus irinotecan-based therapy as well as bevacizumab versus non-bevacizumab therapy). For the assessment of irinotecan- versus oxaliplatin-based treatment, the mIROX arm of the FIRE-1 trial was excluded from the dataset.</p></sec><sec id="mdw261_s2f"><title>statistical analysis</title><p>PFS and OS were assessed by the Kaplan&#x02013;Meier method and compared with log-rank tests. Hazard ratios (HRs) were calculated by the Cox regression models stratified by study and treatment if appropriate. Multivariate tests were carried out using the Cox models adjusted for study treatment, ECOG, sex, adjuvant chemotherapy, liver-limited disease and number of involved organs. Comparisons of patients with mutation variants to patients with wild-type mCRC were adjusted for multiplicity (Dunnett's test). The significance level was set to 0.05. All statistical analyses were carried out using SAS 9.2 (SAS Institute Inc., Cary, NC), IBM SPSS Statistics 22 (IBM Corporation, Armonk, NY) and R (version 3.2.2).</p></sec></sec><sec sec-type="results" id="mdw261_s3"><title>results</title><p>For this analysis, data of 1239 patients were available. Distribution of patients across studies according to molecular characteristics is summarized in Table <xref ref-type="table" rid="MDW261TB1">1</xref>.<table-wrap id="MDW261TB1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Patients and studies</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Original study (recruiting years) [full population]</th><th align="left" rowspan="1" colspan="1">Evaluable subset</th><th align="left" rowspan="1" colspan="1">No mutation, <italic>n</italic> = 664 (%)</th><th align="left" rowspan="1" colspan="1"><italic>KRAS</italic> mutation, <italic>n</italic> = 462 (%)</th><th align="left" rowspan="1" colspan="1"><italic>NRAS</italic> mutation, <italic>n</italic> = 39 (%)</th><th align="left" rowspan="1" colspan="1"><italic>BRAF</italic> mutation, <italic>n</italic> = 74 (%)</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">FIRE-1 (2000&#x02013;2004) [<italic>n</italic> = 479]</td><td rowspan="1" colspan="1">FUFIRI (<italic>n</italic> = 108, 100%)</td><td rowspan="1" colspan="1">45 (41.7)</td><td rowspan="1" colspan="1">55 (50.9)</td><td rowspan="1" colspan="1">7 (6.5)</td><td rowspan="1" colspan="1">1 (0.9)</td></tr><tr><td rowspan="1" colspan="1">mIROX (<italic>n</italic> = 100, 100%)</td><td rowspan="1" colspan="1">48 (48)</td><td rowspan="1" colspan="1">41 (41.0)</td><td rowspan="1" colspan="1">4 (4.0)</td><td rowspan="1" colspan="1">7 (7.0)</td></tr><tr><td rowspan="1" colspan="1">FIRE-3 (2007&#x02013;2012) [<italic>n</italic> = 362]</td><td rowspan="1" colspan="1">FOLFIRI plus bevacizumab (<italic>n</italic> = 283, 100%)</td><td rowspan="1" colspan="1">177 (62.5)</td><td rowspan="1" colspan="1">69 (24.4)</td><td rowspan="1" colspan="1">12 (4.2)</td><td rowspan="1" colspan="1">25 (8.8)</td></tr><tr><td rowspan="2" colspan="1">AIO KRK 0604 (2005&#x02013;2006) [<italic>n</italic> = 255]</td><td rowspan="1" colspan="1">CAPOX plus bevacizumab (<italic>n</italic> = 110, 100%)</td><td rowspan="1" colspan="1">65 (59.0)</td><td rowspan="1" colspan="1">40 (36.4)<sup>a</sup></td><td rowspan="1" colspan="1">n.a</td><td rowspan="1" colspan="1">5 (4.5)</td></tr><tr><td rowspan="1" colspan="1">CAPIRI plus bevacizumab (<italic>n</italic> = 103, 100%)</td><td rowspan="1" colspan="1">72 (70.0)</td><td rowspan="1" colspan="1">30 (29.1)<sup>a</sup></td><td rowspan="1" colspan="1">n.a.</td><td rowspan="1" colspan="1">1 (1.0)</td></tr><tr><td rowspan="3" colspan="1">AIO KRK 0207<sup>b</sup> (2009&#x02013;2013) [<italic>n</italic> = 472]</td><td rowspan="1" colspan="1">Observation (<italic>n</italic> = 115, 100%)</td><td rowspan="1" colspan="1">47 (40.9)</td><td rowspan="1" colspan="1">53 (46.1)</td><td rowspan="1" colspan="1">8 (7.0)</td><td rowspan="1" colspan="1">7 (6.1)</td></tr><tr><td rowspan="1" colspan="1">bevacizumab (<italic>n</italic> = 109, 100%)</td><td rowspan="1" colspan="1">45 (41.3)</td><td rowspan="1" colspan="1">53 (48.6)</td><td rowspan="1" colspan="1">4 (3.7)</td><td rowspan="1" colspan="1">7 (6.4)</td></tr><tr><td rowspan="1" colspan="1">FP plus bevacizumab (<italic>n</italic> = 109, 100%)</td><td rowspan="1" colspan="1">48 (44.0)</td><td rowspan="1" colspan="1">49 (45.0)</td><td rowspan="1" colspan="1">4 (3.7)</td><td rowspan="1" colspan="1">8 (7.3)</td></tr><tr><td rowspan="1" colspan="1">RO91 (2002&#x02013;2004) [<italic>n</italic> = 474]</td><td rowspan="1" colspan="1">CAPOX/FUFOX (<italic>n</italic> = 202)</td><td rowspan="1" colspan="1">117 (57.9)</td><td rowspan="1" colspan="1">72 (35.6)<sup>a</sup></td><td rowspan="1" colspan="1">n.a.</td><td rowspan="1" colspan="1">13 (6.4)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>n.a., not assessed; FP, fluoropyrimindine; percentages in parentheses indicate percentage of molecular subgroups within the respective study(-arm). FUFIRI, infusional 5-FU, folinic acid, irinotecan; mIROX, irinotecan plus oxaliplatin; FOLFIRI, infusional and bolus 5-FU, folinic acid, irinotecan; CAPOX, capecitabine, oxaliplatin; CAPIRI, capecitabine, irinotecan; FUFOX, infusional 5-FU, oxaliplatin.</p></fn><fn id="tblfn2"><p><sup>a</sup>Only tested for KRAS exon 2 mutations.</p></fn><fn id="tblfn3"><p><sup>b</sup>Twenty-four weeks fluoropyrimidine, oxaliplatin plus bevacizumab.</p></fn></table-wrap-foot></table-wrap></p><sec id="mdw261_s3a"><title>mutations</title><p>Of 1239 analyzed tumors, in 664 tumors (53.6%), no mutation was detected, whereas 462 tumors harboring <italic>KRAS</italic> (37.3%) mutations and 39 <italic>NRAS</italic> (3.1%) mutations were found. Additionally, a total of 74 tumors (6.0%) were carrying <italic>BRAF</italic> V600E mutations (<ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdw261/-/DC1">supplementary Table S1, available at <italic>Annals of Oncology</italic> online</ext-link>).</p></sec><sec id="mdw261_s3b"><title>baseline characteristics</title><p>Distributions of baseline characteristics in molecular subgroups are summarized in Table <xref ref-type="table" rid="MDW261TB2">2</xref>.<table-wrap id="MDW261TB2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline characteristics according to molecular subgroups</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">No mutation (<italic>n</italic> = 664)</th><th align="left" rowspan="1" colspan="1"><italic>KRAS</italic> mutation (<italic>n</italic> = 462)</th><th align="left" rowspan="1" colspan="1"><italic>NRAS</italic> mutation (<italic>n</italic> = 39)</th><th align="left" rowspan="1" colspan="1"><italic>BRAF</italic> mutation (<italic>n</italic> = 74)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="6" rowspan="1">Age</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Median (range)</td><td rowspan="1" colspan="1">65 (25&#x02013;82)</td><td rowspan="1" colspan="1">64 (25&#x02013;83)</td><td rowspan="1" colspan="1">64 (32&#x02013;81)</td><td rowspan="1" colspan="1">62 (29&#x02013;82)</td><td rowspan="2" colspan="1">0.17</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr><tr><td colspan="6" rowspan="1">Sex</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Male (%)</td><td rowspan="1" colspan="1">460 (69.3)</td><td rowspan="1" colspan="1">292 (63.2)</td><td rowspan="1" colspan="1">21 (53.8)</td><td rowspan="1" colspan="1">37 (50.7)</td><td rowspan="3" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Female (%)</td><td rowspan="1" colspan="1">204 (30.7)</td><td rowspan="1" colspan="1">170 (36.8)</td><td rowspan="1" colspan="1">18 (46.2)</td><td rowspan="1" colspan="1">36 (49.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td colspan="6" rowspan="1">Primary tumor site</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Colon (%)</td><td rowspan="1" colspan="1">414 (63.1)</td><td rowspan="1" colspan="1">286 (61.9)</td><td rowspan="1" colspan="1">23 (59.0)</td><td rowspan="1" colspan="1">56 (77.8)</td><td rowspan="4" colspan="1">0.06</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Rectum (%)</td><td rowspan="1" colspan="1">236 (36.0)</td><td rowspan="1" colspan="1">175 (37.9)</td><td rowspan="1" colspan="1">15 (38.5)</td><td rowspan="1" colspan="1">15 (20.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Colon + rectum (%)</td><td rowspan="1" colspan="1">6 (0.9)</td><td rowspan="1" colspan="1">1 (0.2)</td><td rowspan="1" colspan="1">1 (2.6)</td><td rowspan="1" colspan="1">1 (1.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td></tr><tr><td colspan="6" rowspan="1">ECOG performance status</td></tr><tr><td rowspan="1" colspan="1">&#x02003;0 (%)</td><td rowspan="1" colspan="1">340 (51.3)</td><td rowspan="1" colspan="1">225 (49.7)</td><td rowspan="1" colspan="1">18 (46.2)</td><td rowspan="1" colspan="1">33 (45.8)</td><td rowspan="4" colspan="1">0.64</td></tr><tr><td rowspan="1" colspan="1">&#x02003;1 (%)</td><td rowspan="1" colspan="1">297 (44.8)</td><td rowspan="1" colspan="1">206 (45.5)</td><td rowspan="1" colspan="1">20 (51.3)</td><td rowspan="1" colspan="1">33 (45.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;2 (%)</td><td rowspan="1" colspan="1">26 (3.9)</td><td rowspan="1" colspan="1">22 (4.9)</td><td rowspan="1" colspan="1">1 (2.6)</td><td rowspan="1" colspan="1">6 (8.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td></tr><tr><td colspan="6" rowspan="1">Prior adjuvant treatment</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Adjuvant treatment (%)</td><td rowspan="1" colspan="1">140 (21.1)</td><td rowspan="1" colspan="1">87 (18.9)</td><td rowspan="1" colspan="1">10 (25.6)</td><td rowspan="1" colspan="1">11 (15.1)</td><td rowspan="2" colspan="1">0.43</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td colspan="6" rowspan="1">Metastatic lesions</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Liver (%)</td><td rowspan="1" colspan="1">550 (83.2)</td><td rowspan="1" colspan="1">366 (80.6)</td><td rowspan="1" colspan="1">33 (84.6)</td><td rowspan="1" colspan="1">57 (78.1)</td><td rowspan="2" colspan="1">0.54</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Liver limited (%)</td><td rowspan="1" colspan="1">290 (43.9)</td><td rowspan="1" colspan="1">164 (36.1)</td><td rowspan="1" colspan="1">15 (38.5)</td><td rowspan="1" colspan="1">22 (30.1)</td><td rowspan="2" colspan="1">0.02</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Lung (%)</td><td rowspan="1" colspan="1">196 (29.7)</td><td rowspan="1" colspan="1">184 (40.5)</td><td rowspan="1" colspan="1">13 (33.3)</td><td rowspan="1" colspan="1">17 (23.3)</td><td rowspan="2" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Peritoneum</td><td rowspan="1" colspan="1">30 (5.5)</td><td rowspan="1" colspan="1">20 (5.2)</td><td rowspan="1" colspan="1">5 (12.8)</td><td rowspan="1" colspan="1">12 (20.0)</td><td rowspan="2" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data</td><td rowspan="1" colspan="1">120</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">14</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Lymph nodes</td><td rowspan="1" colspan="1">80 (29.7)</td><td rowspan="1" colspan="1">29 (17.8)</td><td rowspan="1" colspan="1">9 (39.1)</td><td rowspan="1" colspan="1">13 (40.6)</td><td rowspan="2" colspan="1">0.005</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data</td><td rowspan="1" colspan="1">395</td><td rowspan="1" colspan="1">299</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">42</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003e;2 organs involved</td><td rowspan="1" colspan="1">99 (15.0)</td><td rowspan="1" colspan="1">77 (17.0)</td><td rowspan="1" colspan="1">11 (28.9)</td><td rowspan="1" colspan="1">15 (20.5)</td><td rowspan="2" colspan="1">0.10</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="tblfn4"><p><italic>P</italic> values by <italic>&#x003c7;</italic><sup>2</sup> tests, except for age: Wilcoxon's test. Calculations based on non-missing data. Metastastic spread reported to different extent in studies with evaluable data for all trials concerning liver and lung metastases and no of involved organs. Karnofsky performance status was translated into ECOG for the FIRE-1 study: Karnofsky 100 = ECOG 0; Karnofsky 80&#x02013;90 = ECOG 1; Karnofsky 70 = ECOG 2.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="mdw261_s3c"><title>prognostic role of KRAS, NRAS and BRAF mutation</title><p>PFS and OS were significantly influenced by molecular subgroups (Figures <xref ref-type="fig" rid="MDW261F1">1</xref>A and B and <xref ref-type="fig" rid="MDW261F2">2</xref>A and B). Univariate and multivariate comparisons of PFS and OS in patients with mutant tumors (<italic>KRAS</italic>, <italic>NRAS</italic>, <italic>BRAF</italic>) versus patients with non-mutated tumors revealed a negative prognostic effect of <italic>KRAS</italic> and <italic>BRAF</italic> mutations (Figure <xref ref-type="fig" rid="MDW261F2">2</xref>A and B). Interestingly, the negative prognostic role of <italic>KRAS</italic> and <italic>BRAF</italic> mutations was consistently observed across different treatment regimens (subgroups of irinotecan- and oxaliplatin-treated as well as in bevacizumab- and non-bevacizumab-treated) (Figure <xref ref-type="fig" rid="MDW261F2">2</xref>A and B).<fig id="MDW261F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Prognostic role of alterations in <italic>KRAS-, NRAS-</italic> and <italic>BRAF</italic>-genes. (A) Progression-free survival (PFS) according to molecular subgroups. (B) Overall survival (OS) according to molecular subgroups. (C) PFS in <italic>KRAS</italic> exon 2 variants. (D) OS in <italic>KRAS</italic> exon 2 variants, <italic>P</italic> values below 0.05 by log-rank test indicate at least one significant difference between two groups.</p></caption><graphic xlink:href="mdw26101"/></fig><fig id="MDW261F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Forest plots of metastatic colorectal cancer (mCRC) molecular subgroups as well as mutation variants compared with <italic>KRAS</italic>/<italic>NRAS</italic>/<italic>BRAF</italic> wild-type mCRC. (A) Progression-free survival (PFS) according to molecular subgroups. (B) Overall survival (OS) according to molecular subgroups. (C) PFS according to mutation variants. (D) OS according to mutation variants; hazard ratios (HR) with 95% confidence intervals (95% CI) adjusted for multiplicity indicate results drawn from the multivariate model. An HR &#x0003e;1 indicates a higher hazard rate for death or progression in patients with mutated tumors compared with patients with unmutated tumors. Only mutation variants with &#x0003e;10 patients were included into the analysis in C and D. All variants in C and D represent respective <italic>KRAS</italic> mutations except NG12D, <italic>NRAS</italic> G12D; V600E, <italic>BRAF</italic> V600E; bev., bevacizumab; WT, unmutated tumors.</p></caption><graphic xlink:href="mdw26102a"/><graphic xlink:href="mdw26102b"/><graphic xlink:href="mdw26102cd"/></fig></p></sec><sec id="mdw261_s3d"><title>prognostic role of single RAS mutation variants</title><p>The median PFS of patients with <italic>KRAS</italic> exon 2 mutant tumor subtypes ranged from 8.8 [95% confidence interval (CI) 7.6&#x02013;10.0] months (G13D mutation) to 10.5 (95% CI 9.0&#x02013;11.9) months in (G12D variants). The median OS widely ranged between 16.8 (95% CI 15.6&#x02013;18.0) months (G12C) and 25.2 (95% CI 22.2&#x02013;28.2) (G12D variants) (Figure <xref ref-type="fig" rid="MDW261F1">1</xref>C and D). Besides <italic>KRAS</italic> exon 2 variants, <italic>KRAS</italic> mutations A146T (<italic>n</italic> = 18) and Q61H (<italic>n</italic> = 17) as well as <italic>NRAS</italic> mutation G12D (<italic>n</italic> = 11) were separately evaluated for efficacy end points, all other variants were less frequent (<ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdw261/-/DC1">supplementary Table S1, available at <italic>Annals of Oncology</italic> online</ext-link>).</p><p>Comparisons of PFS and OS (univariate and multivariate) of patients with mutation variants to patients with non-mutated tumors revealed the <italic>KRAS</italic> exon 2 G12C-variant (<italic>n</italic> = 28) to correlate with inferior OS compared with non-mutated tumors [multivariate model HR 2.26 (1.25&#x02013;4.1), <italic>P</italic> = 0.001] (Figure <xref ref-type="fig" rid="MDW261F2">2</xref>C and D). A similar trend was seen in the <italic>KRAS</italic> exon 2 G13D-variant [<italic>n</italic> = 71, multivariate model HR 1.46 (0.96&#x02013;2.22), <italic>P</italic> = 0.10]. More frequent <italic>KRAS</italic> exon 2 variants like G12D [<italic>n</italic> = 152, multivariate model HR 1.17 (0.86&#x02013;1.6), <italic>P</italic> = 0.81] and G12V [<italic>n</italic> = 92, multivariate model HR 1.27 (0.87&#x02013;1.86), <italic>P</italic> = 0.57] did not have significant impact on OS. The G12V mutation variant had a negative prognostic effect on PFS in the multivariate analysis (Figure <xref ref-type="fig" rid="MDW261F2">2</xref>C).</p></sec></sec><sec sec-type="discussion" id="mdw261_s4"><title>discussion</title><p>The present analysis was motivated by the limited clinical data regarding the prognostic impact of <italic>RAS</italic> mutation variants in patients with mCRC receiving first-line systemic treatment without EGFR-targeted therapy. Our analysis comprises data of 1239 patients and therefore represents one of the largest datasets available.</p><p><italic>KRAS</italic> (37.3%) and <italic>NRAS</italic> (3.1%) mutations were a little less frequent in our cohort compared with other series. [<xref rid="MDW261C1" ref-type="bibr">1</xref>, <xref rid="MDW261C22" ref-type="bibr">22</xref>]. Selection of <italic>KRAS</italic> exon 2 wild-type for inclusion in the FIRE-3 trial as well as lack of testing for <italic>KRAS</italic> exon 3&#x02013;4 and <italic>NRAS</italic> exon 2&#x02013;4 in AIO KRK 0604 and RO91 may have contributed to this result. The lack of testing in these two studies might cause a small negative bias on outcome of patients with unmutated tumors.</p><p>Baseline characteristics compared between molecular subgroups reflected more aggressive disease in patients with mutated tumors (in particular in patients with <italic>BRAF</italic>-mutant mCRC). <italic>BRAF</italic> mutation seemed associated with female sex and tumor location (colon). These results confirm previous observations [<xref rid="MDW261C23" ref-type="bibr">23</xref>].</p><p>PFS of patients evaluated by molecular subgroups demonstrated a strong negative prognostic effect of <italic>BRAF</italic> mutation (HR 2.19, <italic>P</italic> &#x0003c; 0.0001) as well as a smaller, but also significant negative effect of <italic>KRAS</italic> mutation, both compared with non-mutated tumors (HR 1.2, <italic>P</italic> = 0.03). The differences in outcome associated with molecular subtype were pronounced in OS. Of note, the median OS reported in patients with non-mutated tumors was 26.9 (95% CI 25.2&#x02013;28.5) months. Taking into account that not all patients had access to EGFR-targeted agents since these were partly unavailable at the time of study conduct of FIRE-1/RO91, this result compares well with recent reports of first-line treatment in mCRC [<xref rid="MDW261C5" ref-type="bibr">5</xref>, <xref rid="MDW261C24" ref-type="bibr">24</xref>]. Outcome of patients with <italic>KRAS</italic> or <italic>BRAF</italic>-mutant mCRC demonstrated significantly shorter medians of OS: 21.0 (18.5&#x02013;23.5) and 11.7 (9.7&#x02013;13.6) months, respectively, translating to HRs of 1.41 (<italic>P</italic> &#x0003c; 0.001) for KRAS and 2.99 (<italic>P</italic> &#x0003c; 0.001) for <italic>BRAF</italic>. Availability of later-line treatment (i.e. EGFR-targeted agents) in patients with non-mutated tumors might have impacted on OS for those patients. However, the also present differences in PFS in patients with non-mutated tumors compared with patients with <italic>KRAS</italic>-mutant mCRC support the hypothesis that <italic>KRAS</italic> is a prognostic factor <italic>per se</italic> and differences in outcome are not only mediated by a subset of patients receiving later-line EGFR-inhibitors. The number of patients with <italic>NRAS</italic>-mutant tumors in this dataset was probably too small to allow for significant effects on outcome.</p><p>In this pooled dataset, the prognostic effect of molecular subgroups (i.e. <italic>KRAS</italic> and <italic>BRAF</italic> mutation) in comparison with non-mutated tumors was consistently observed in all subsets of patients being treated with irinotecan- or oxaliplatin combinations as well as in bevacizumab- or non-bevacizumab-treated patient. Considering that microsatellite-instable tumors are rare in stage IV mCRC, these findings compare well with a recent analysis of the adjuvant PETACC-8-trial that identified <italic>KRAS</italic> and <italic>BRAF</italic> mutations as prognostic markers in microsatellite-stable (but not microsatellite-instable) tumors [<xref rid="MDW261C25" ref-type="bibr">25</xref>]. Further classification of mCRC might be seen in differentiation of left-sided versus right-sided primary tumor location, probably being a surrogate for molecular profiles that have not been understood in full extent [<xref rid="MDW261C26" ref-type="bibr">26</xref>]. Unfortunately, primary tumor location was not recorded during study conduct for the majority of patients in this cohort and cannot be taken into account for our analysis.</p><p><italic>KRAS</italic> exon 2 mutation variants were associated with heterogeneous outcome concerning OS as well as PFS. The G12V mutation variant, representing one of the most frequent subtypes, was associated with a significantly worse PFS compared with patients without any mutation (HR = 1.48, <italic>P</italic> = 0.02). OS was also inferior&#x02014;however not significant&#x02014;in G12V and G13D 1 subtypes, and significantly inferior in G12C mutations variants compared with patients with non-mutated tumors. This observation supports the hypothesis that <italic>KRAS</italic> exon 2 mutation variants are associated with a differing spectrum of clinical outcome [<xref rid="MDW261C4" ref-type="bibr">4</xref>, <xref rid="MDW261C8" ref-type="bibr">8</xref>, <xref rid="MDW261C27" ref-type="bibr">27</xref>]. It might be speculated that the reason for differing outcomes could be mediated by differing activation of <italic>KRAS</italic>-depending pathways by distinct mutation variants, as suggested previously with high baseline activation and potentially aggressive biology in G12C variants [<xref rid="MDW261C28" ref-type="bibr">28</xref>]. In addition, the poor outcome of patients with G12C mutant mCRC might be of clinical relevance as allele-specific inhibitors may provide therapeutic options in the future [<xref rid="MDW261C29" ref-type="bibr">29</xref>, <xref rid="MDW261C30" ref-type="bibr">30</xref>]. In this context, also the mutation rate of <italic>KRAS</italic> could be a factor that impacts significantly on prognosis of <italic>KRAS</italic>-mutant mCRC [<xref rid="MDW261C31" ref-type="bibr">31</xref>]. Unfortunately, this information is not available for our cohort.</p><p>In general, despite high data quality, pooled datasets of different randomized trials may always lead to cohorts with study-specific bias. Although multivariate models can adjust calculations for some (obvious) factors, retrospectively evaluated, pooled data invoke uncertainties. Pooling data from five studies has enlarged the number of some mutation variants (i.e. <italic>NRAS</italic> as well as <italic>KRAS</italic> exon 2 mutation variants) to a level that consecutively enabled survival analysis. However, absolute numbers in these subgroups are still unsatisfactory and the analyses appear underpowered to allow for definite conclusions, especially in rare mutation variants. In particular, false-negative results cannot be excluded as potential limitations in this setting. Given that some biomarkers (i.e. <italic>KRAS</italic> mutation variants) were identified as potential prognostic markers, validation of our findings within alternative study-sets appears justified.</p><p>In conclusion, our data suggest that mutations in <italic>KRAS</italic> and <italic>BRAF</italic> are associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. Whereas role of chemotherapy and treatment with or without bevacizumab did not affect these findings, <italic>KRAS</italic> exon 2 mutation variants differed, with G12C being associated with shorter OS when compared with patients with non-mutated tumors, while G13D mutations were showing a similar trend.</p></sec><sec id="mdw261_s5"><title>funding</title><p>FIRE-1 was supported by Pfizer; FIRE-3 was supported by Merck and Pfizer; RO91 and AIOKRK0604 were supported by Roche and Sanofi; AIOKRK0207 was supported by Roche. The present evaluation did not receive specific funding and the funding sources did not contribute to this evaluation.</p></sec><sec id="mdw261_s6"><title>disclosure</title><p>DPM: honoraria: Merck, Roche, Amgen, Bayer; advisory role: Merck, Bayer, Amgen; research grant: Amgen (inst), Merck (inst), Roche (inst); travel support: Amgen, Merck, Sanofi, Bayer.</p><p>VH: honoraria: Merck, Roche, Amgen, Sirtex, Sanofi-aventis; advisory role: Merck, Roche, Amgen, Sirtex, Sanofi-aventis; research funding: Amgen, Merck, Roche, Sanofi-Aventis; travel support: Merck, Roche. SS: honoraria: Merck, Roche, Amgen, Bayer, Sanofi-aventis; advisory role: Merck Serono, Roche; travel support: Roche, Merck Serono, Sanofi-aventis. UG: honoraria: Amgen, Roche, Merck, Sanofi, Bayer. DA: honoraria: Bayer, Merck, Roche, Sanofi; advisory role: Roche, Bayer, Merck, Servier, Sandoz ARS: honoraria: Pfizer, Sanofi-Aventis, Merck, Celgene, Amgen, Roche; advisory role: Amgen, Roche, Pfizer, Sanofi-Aventis, Merck, Celgene; research support: Roche, Sanofi-Aventis, Celgene. All remaining authors have declared no conflicts of interest.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_27_9_1746__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="supp_mdw261_mdw261supp_table1.docx"/>
</supplementary-material>
</sec>
</body><back><ack><title>acknowledgements</title><p>The authors thank all patients and families for participation in the studies, as well as all involved study centers, colleagues and nurses.</p></ack><ref-list><title>references</title><ref id="MDW261C1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Douillard</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Oliner</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Siena</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer</article-title>. <source>N Engl J Med</source>
<year>2013</year>; <volume>369</volume>: <fpage>1023</fpage>&#x02013;<lpage>1034</lpage>.<pub-id pub-id-type="pmid">24024839</pub-id></mixed-citation></ref><ref id="MDW261C2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinemann</surname><given-names>V</given-names></name>, <name name-style="western"><surname>von Weikersthal</surname><given-names>LF</given-names></name>, <name name-style="western"><surname>Decker</surname><given-names>T</given-names></name><etal>et al</etal></person-group>
<article-title>FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial</article-title>. <source>Lancet Oncol</source>
<year>2014</year>; <volume>15</volume>: <fpage>1065</fpage>&#x02013;<lpage>1075</lpage>.<pub-id pub-id-type="pmid">25088940</pub-id></mixed-citation></ref><ref id="MDW261C3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Cutsem</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lenz</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Kohne</surname><given-names>CH</given-names></name><etal>et al</etal></person-group>
<article-title>Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer</article-title>. <source>J Clin Oncol</source>
<year>2015</year>; <volume>33</volume>: <fpage>692</fpage>&#x02013;<lpage>700</lpage>.<pub-id pub-id-type="pmid">25605843</pub-id></mixed-citation></ref><ref id="MDW261C4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bazan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Migliavacca</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zanna</surname><given-names>I</given-names></name><etal>et al</etal></person-group>
<article-title>Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype</article-title>. <source>Ann Oncol</source>
<year>2002</year>; <volume>13</volume>: <fpage>1438</fpage>&#x02013;<lpage>1446</lpage>.<pub-id pub-id-type="pmid">12196370</pub-id></mixed-citation></ref><ref id="MDW261C5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cremolini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Loupakis</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Antoniotti</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study</article-title>. <source>Lancet Oncol</source>
<year>2015</year>; <volume>16</volume>: <fpage>1306</fpage>&#x02013;<lpage>1315</lpage>.<pub-id pub-id-type="pmid">26338525</pub-id></mixed-citation></ref><ref id="MDW261C6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Roock</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Claes</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bernasconi</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis</article-title>. <source>Lancet Oncol</source>
<year>2010</year>; <volume>11</volume>: <fpage>753</fpage>&#x02013;<lpage>762</lpage>.<pub-id pub-id-type="pmid">20619739</pub-id></mixed-citation></ref><ref id="MDW261C7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bokemeyer</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bondarenko</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Hartmann</surname><given-names>JT</given-names></name><etal>et al</etal></person-group>
<article-title>Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study</article-title>. <source>Ann Oncol</source>
<year>2011</year>; <volume>22</volume>: <fpage>1535</fpage>&#x02013;<lpage>1546</lpage>.<pub-id pub-id-type="pmid">21228335</pub-id></mixed-citation></ref><ref id="MDW261C8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modest</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Brodowicz</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Stintzing</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials</article-title>. <source>Oncology</source>
<year>2012</year>; <volume>83</volume>: <fpage>241</fpage>&#x02013;<lpage>247</lpage>.<pub-id pub-id-type="pmid">22948721</pub-id></mixed-citation></ref><ref id="MDW261C9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peeters</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Douillard</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Van Cutsem</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab</article-title>. <source>J Clin Oncol</source>
<year>2013</year>; <volume>31</volume>: <fpage>759</fpage>&#x02013;<lpage>765</lpage>.<pub-id pub-id-type="pmid">23182985</pub-id></mixed-citation></ref><ref id="MDW261C10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tejpar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Celik</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Schlichting</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab</article-title>. <source>J Clin Oncol</source>
<year>2012</year>; <volume>30</volume>: <fpage>3570</fpage>&#x02013;<lpage>3577</lpage>.<pub-id pub-id-type="pmid">22734028</pub-id></mixed-citation></ref><ref id="MDW261C11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Cutsem</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kohne</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>I</given-names></name><etal>et al</etal></person-group>
<article-title>Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status</article-title>. <source>J Clin Oncol</source>
<year>2011</year>; <volume>29</volume>: <fpage>2011</fpage>&#x02013;<lpage>2019</lpage>.<pub-id pub-id-type="pmid">21502544</pub-id></mixed-citation></ref><ref id="MDW261C12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seligmann</surname><given-names>J</given-names></name></person-group>
<article-title>Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced colorectal cancer (aCRC): analysis from 2,530 patients (pts) in randomized clinical trials (RCTs)</article-title>. <source>J Clin Oncol</source>
<year>2015</year>; <volume>33</volume> (<comment>Suppl): abstr 3509</comment>.</mixed-citation></ref><ref id="MDW261C13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corcoran</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Atreya</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Falchook</surname><given-names>GS</given-names></name><etal>et al</etal></person-group>
<article-title>Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer</article-title>. <source>J Clin Oncol</source>
<year>2015</year>; <volume>33</volume>: <fpage>4023</fpage>&#x02013;<lpage>4031</lpage>.<pub-id pub-id-type="pmid">26392102</pub-id></mixed-citation></ref><ref id="MDW261C14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer von Weikersthal</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Schalhorn</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Stauch</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer</article-title>. <source>Eur J Cancer</source>
<year>2011</year>; <volume>47</volume>: <fpage>206</fpage>&#x02013;<lpage>214</lpage>.<pub-id pub-id-type="pmid">20971632</pub-id></mixed-citation></ref><ref id="MDW261C15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stahler</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Heinemann</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Giessen-Jung</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)</article-title>. <source>Int J Cancer</source>
<year>2016</year>; <volume>138</volume>: <fpage>739</fpage>&#x02013;<lpage>746</lpage>.<pub-id pub-id-type="pmid">26284333</pub-id></mixed-citation></ref><ref id="MDW261C16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stintzing</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fischer von Weikersthal</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Decker</surname><given-names>T</given-names></name><etal>et al</etal></person-group>
<article-title>FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306</article-title>. <source>Ann Oncol</source>
<year>2012</year>; <volume>23</volume>: <fpage>1693</fpage>&#x02013;<lpage>1699</lpage>.<pub-id pub-id-type="pmid">22219013</pub-id></mixed-citation></ref><ref id="MDW261C17"><label>17</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Stintzing</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rossius</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Modest</surname><given-names>DP</given-names></name><etal>et al</etal></person-group>
<article-title>Analysis of KRAS/NRAS and BRAF mutations in FIRE-3 A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients</article-title>. In <conf-name>ESMO/ECCO</conf-name>, <year>2013</year>; <comment>Abstract E17-7073</comment>.</mixed-citation></ref><ref id="MDW261C18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmiegel</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Reinacher-Schick</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Arnold</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group</article-title>. <source>Ann Oncol</source>
<year>2013</year>; <volume>24</volume>: <fpage>1580</fpage>&#x02013;<lpage>1587</lpage>.<pub-id pub-id-type="pmid">23463625</pub-id></mixed-citation></ref><ref id="MDW261C19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hegewisch-Becker</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Graeven</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Lerchenmuller</surname><given-names>CA</given-names></name><etal>et al</etal></person-group>
<article-title>Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial</article-title>. <source>Lancet Oncol</source>
<year>2015</year>; <volume>16</volume>: <fpage>1355</fpage>&#x02013;<lpage>1369</lpage>.<pub-id pub-id-type="pmid">26361971</pub-id></mixed-citation></ref><ref id="MDW261C20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porschen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Arkenau</surname><given-names>HT</given-names></name>, <name name-style="western"><surname>Kubicka</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group</article-title>. <source>J Clin Oncol</source>
<year>2007</year>; <volume>25</volume>: <fpage>4217</fpage>&#x02013;<lpage>4223</lpage>.<pub-id pub-id-type="pmid">17548840</pub-id></mixed-citation></ref><ref id="MDW261C21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinacher-Schick</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schulmann</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Modest</surname><given-names>DP</given-names></name><etal>et al</etal></person-group>
<article-title>Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group</article-title>. <source>BMC Cancer</source>
<year>2012</year>; <volume>12</volume>: <fpage>349</fpage>.<pub-id pub-id-type="pmid">22876876</pub-id></mixed-citation></ref><ref id="MDW261C22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neumann</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zeindl-Eberhart</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kirchner</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>A</given-names></name></person-group>
<article-title>Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer</article-title>. <source>Pathol Res Pract</source>
<year>2009</year>; <volume>205</volume>: <fpage>858</fpage>&#x02013;<lpage>862</lpage>.<pub-id pub-id-type="pmid">19679400</pub-id></mixed-citation></ref><ref id="MDW261C23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokota</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ura</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Shibata</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer</article-title>. <source>Br J Cancer</source>
<year>2011</year>; <volume>104</volume>: <fpage>856</fpage>&#x02013;<lpage>862</lpage>.<pub-id pub-id-type="pmid">21285991</pub-id></mixed-citation></ref><ref id="MDW261C24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simkens</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>van Tinteren</surname><given-names>H</given-names></name>, <name name-style="western"><surname>May</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group</article-title>. <source>Lancet</source>
<year>2015</year>; <volume>385</volume>: <fpage>1843</fpage>&#x02013;<lpage>1852</lpage>.<pub-id pub-id-type="pmid">25862517</pub-id></mixed-citation></ref><ref id="MDW261C25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taieb</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zaanan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Le Malicot</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Prognostic effect of BRAF and KRAS mutations in patients with stage iii colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial</article-title>. <source>JAMA Oncol</source>
<year>2016</year>; <fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">26768652</pub-id></mixed-citation></ref><ref id="MDW261C26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Missiaglia</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>B</given-names></name>, <name name-style="western"><surname>D'Ario</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features</article-title>. <source>Ann Oncol</source>
<year>2014</year>; <volume>25</volume>: <fpage>1995</fpage>&#x02013;<lpage>2001</lpage>.<pub-id pub-id-type="pmid">25057166</pub-id></mixed-citation></ref><ref id="MDW261C27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Roock</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Jonker</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Di Nicolantonio</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab</article-title>. <source>JAMA</source>
<year>2010</year>; <volume>304</volume>: <fpage>1812</fpage>&#x02013;<lpage>1820</lpage>.<pub-id pub-id-type="pmid">20978259</pub-id></mixed-citation></ref><ref id="MDW261C28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camaj</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Primo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>
<article-title>KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer</article-title>. <source>Future Oncol</source>
<year>2015</year>; <volume>11</volume>: <fpage>1919</fpage>&#x02013;<lpage>1929</lpage>.<pub-id pub-id-type="pmid">26161928</pub-id></mixed-citation></ref><ref id="MDW261C29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lito</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Solomon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>LS</given-names></name><etal>et al</etal></person-group>
<article-title>Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</article-title>. <source>Science</source>
<year>2016</year>; <volume>351</volume>: <fpage>604</fpage>&#x02013;<lpage>608</lpage>.<pub-id pub-id-type="pmid">26841430</pub-id></mixed-citation></ref><ref id="MDW261C30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ostrem</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Sos</surname><given-names>ML</given-names></name><etal>et al</etal></person-group>
<article-title>K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions</article-title>. <source>Nature</source>
<year>2013</year>; <volume>503</volume>: <fpage>548</fpage>&#x02013;<lpage>551</lpage>.<pub-id pub-id-type="pmid">24256730</pub-id></mixed-citation></ref><ref id="MDW261C31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vincenzi</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Cremolini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sartore-Bianchi</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients</article-title>. <source>Oncotarget</source>
<year>2015</year>; <volume>6</volume>: <fpage>31604</fpage>&#x02013;<lpage>31612</lpage>.<pub-id pub-id-type="pmid">26384309</pub-id></mixed-citation></ref></ref-list></back></article>